Healthcare
What’s One SOP or Protocol You Wish Every Cleanroom Leader Would Rethink
Too many cleanroom teams still assume that more disinfectant is the answer, but Annex 1 makes it clear that residues left behind can quietly undermine even the most aggressive cleaning regimes. Without a deliberate residue breakdown step—such as a validated rinse—bioburden can persist beneath the surface, driving CFU formation and downstream environmental monitoring failures….
This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.
Key takeaways
Residue from disinfectants can undermine cleaning by allowing bioburden to persist.
Annex 1 guidelines suggest the need for a deliberate residue breakdown step.
Rethinking SOPs can improve cleanroom performance by addressing hidden residues.
Too many cleanroom teams still assume that more disinfectant is the answer, but Annex 1 makes it clear that residues left behind can quietly undermine even the most aggressive cleaning regimes. Without a deliberate residue breakdown step—such as a validated rinse—bioburden can persist beneath the surface, driving CFU formation and downstream environmental monitoring failures. Rethinking this SOP isn’t about adding effort; it’s about removing what’s hiding in plain sight so cleanrooms can perform as designed.
About the author
As a Business Development Representative in the life sciences industry at Benchmark Products, Will specialize in helping companies achieve Annex 1 compliance and cGMP standards by addressing bioburden in cleanroom facilities. Our diverse product range includes pharmaceutical manufacturing supplies, cleaning materials, and cleanroom apparel. Benchmark Products offers advanced cleanroom technologies designed to enhance efficiency, quality, and cost-effectiveness, serving over 500 life science customers with tailored solutions. Our offerings support pharmaceutical manufacturing for sterile injectables, biopharmaceuticals, solid dose and HPAPIs, cell/gene therapies, radiopharmaceuticals, medical devices, and combination drug products.
